Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.56 |
| ▸ | KDM6B | O15054 | 9/20 | 0.56 |
| ▸ | KDM4D | Q6B0I6 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | KDM4A | O75164 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.49 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.49 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.49 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.49 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569204 | 0.87 | CDC7 (0.51) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL258224 | 0.86 | KDM6B (0.59) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL22189609 | 0.85 | KDM4C (0.45) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL29581046 | 0.85 | KDM4C (0.45) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL6387642 | 0.85 | KDM4C (0.60) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL9869588 | 0.83 | CYP11B1 (0.45) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL15286584 | 0.82 | KDM4C (0.62) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL6276352 | 0.82 | KDM4C (0.45) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL29581291 | 0.81 | KDM4E (0.46) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL22189337 | 0.81 | KDM4E (0.46) | KDM4CKDM6BKDM4DKDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-112105354-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3723753-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-7368569-B2 | Process for making spirolactone compounds | MERCK & CO., INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060241299-A1 | Process for making spirolactone compounds | VOLANTE RALPH P | 2006-10-26 | — | — | US | disclosed |
| US-20060014950-A1 | Process for Making Spirolactone Compounds | MERCK SHARP & DOHME CORP. | 2006-01-19 | — | — | US | disclosed |
| EP-1558605-A2 | PROCESS FOR MAKING SPIROLACTONE COMPOUNDS | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004104009-A1 | PROCESS FOR MAKING SPIROLACTONE COMPOUNDS | MERCK & CO., INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004037170-A2 | PROCESS FOR MAKING SPIROLACTONE COMPOUNDS | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241299-A1 | Process for making spirolactone compounds | HSD17B7, SDHB, SDHA | KDM4C 3723/4885KDM6B 3035/4885KDM4D 3671/4885 |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | KDM4C 3750/4885KDM6B 2799/4885KDM4D 3469/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | KDM4C 3750/4885KDM6B 2799/4885KDM4D 3469/4885 |
| US-20060014950-A1 | Process for Making Spirolactone Compounds | HSD17B7, CYP17A1, REN | KDM4C 2504/4885KDM6B 2784/4885KDM4D 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.